1244 GMT - Roche Holding no longer expects sales growth for eye drug Vabysmo to rebound in the U.S. this year, which might raise concerns, UBS analysts say in a research note. The Swiss drugmaker now expects Vabysmo to grow by a mid-single-digit percentage in the U.S. and by double digits outside the U.S., according to UBS. "There may be some concern about the revised expectation for Vabysmo's growth trajectory in the U.S. but the company does still expect [about 6 billion Swiss francs] peak sales," the analysts say. Shares rise 2.1%. (adria.calatayud@wsj.com)
(END) Dow Jones Newswires
July 23, 2026 08:44 ET (12:44 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments